Atai Life Sciences Valuation
Is 9VC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9VC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 9VC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 9VC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9VC?
Key metric: As 9VC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 9VC's PB Ratio? | |
|---|---|
| PB Ratio | 1.9x |
| Book | US$145.72m |
| Market Cap | US$281.91m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 673.1x |
| Enterprise Value/EBITDA | -2.1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 9VC's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.2x | ||
PSG PharmaSGP Holding | 9.3x | 13.9% | €304.6m |
APPH Apontis Pharma | 2.6x | 78.1% | €81.1m |
2FJ0 Pierrel | 3.6x | n/a | €92.8m |
HIGH Cantourage Group | 1.3x | 112.7% | €57.9m |
9VC Atai Life Sciences | 1.9x | 34.6% | €281.9m |
Price-To-Book vs Peers: 9VC is good value based on its Price-To-Book Ratio (1.9x) compared to the peer average (4.2x).
Price to Book Ratio vs Industry
How does 9VC's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 11 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: 9VC is good value based on its Price-To-Book Ratio (1.9x) compared to the European Pharmaceuticals industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is 9VC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 9VC's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.68 | €7.55 +350.2% | 31.9% | €10.39 | €4.72 | n/a | 4 |
| Nov ’25 | €0.96 | €8.37 +771.3% | 43.5% | €13.57 | €4.52 | n/a | 4 |
| Oct ’25 | €1.02 | €8.37 +718.5% | 43.5% | €13.57 | €4.52 | n/a | 4 |
| Sep ’25 | €1.16 | €8.37 +620.9% | 43.5% | €13.57 | €4.52 | n/a | 4 |
| Aug ’25 | €1.40 | €8.77 +524.9% | 39.7% | €13.85 | €5.54 | n/a | 4 |
| Jul ’25 | €1.23 | €10.89 +783.3% | 48.4% | €19.38 | €5.54 | n/a | 5 |
| Jun ’25 | €1.37 | €10.89 +697.3% | 48.4% | €19.38 | €5.54 | n/a | 5 |
| May ’25 | €1.81 | €10.89 +500.2% | 48.4% | €19.38 | €5.54 | n/a | 5 |
| Apr ’25 | €1.64 | €13.36 +715.6% | 43.2% | €19.34 | €5.53 | n/a | 4 |
| Mar ’25 | €1.80 | €11.58 +542.8% | 53.5% | €19.26 | €4.68 | n/a | 5 |
| Feb ’25 | €1.63 | €11.58 +608.9% | 53.5% | €19.26 | €4.68 | n/a | 5 |
| Jan ’25 | €1.36 | €11.58 +750.9% | 53.5% | €19.26 | €4.68 | n/a | 5 |
| Dec ’24 | €0.97 | €11.39 +1,068.5% | 50.1% | €19.36 | €4.70 | n/a | 6 |
| Nov ’24 | €1.16 | €11.38 +884.2% | 47.3% | €19.65 | €4.77 | €0.96 | 7 |
| Oct ’24 | €1.22 | €11.38 +830.7% | 47.3% | €19.65 | €4.77 | €1.02 | 7 |
| Sep ’24 | €1.40 | €10.55 +652.4% | 49.0% | €19.25 | €4.67 | €1.16 | 8 |
| Aug ’24 | €1.87 | €11.05 +490.5% | 40.9% | €18.93 | €4.60 | €1.40 | 10 |
| Jul ’24 | €1.55 | €11.04 +610.7% | 40.7% | €19.37 | €4.70 | €1.23 | 11 |
| Jun ’24 | €1.59 | €11.04 +592.4% | 40.7% | €19.37 | €4.70 | €1.37 | 11 |
| May ’24 | €1.73 | €10.86 +526.5% | 40.7% | €19.06 | €4.63 | €1.81 | 11 |
| Apr ’24 | €1.68 | €10.96 +551.4% | 39.1% | €19.37 | €4.70 | €1.64 | 12 |
| Mar ’24 | €1.52 | €11.74 +670.4% | 37.3% | €19.38 | €4.71 | €1.80 | 12 |
| Feb ’24 | €1.64 | €11.74 +617.2% | 37.3% | €19.38 | €4.71 | €1.63 | 12 |
| Jan ’24 | €2.37 | €20.77 +776.0% | 46.1% | €47.11 | €6.22 | €1.36 | 13 |
| Dec ’23 | €3.21 | €22.70 +606.4% | 46.9% | €49.06 | €6.48 | €0.97 | 12 |
| Nov ’23 | €3.57 | €23.58 +561.4% | 46.0% | €50.61 | €6.68 | €1.16 | 12 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.9b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$15.55
7D
1.6%
1Y
73.9%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
0.4%
1Y
-33.2%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.45
7D
1.1%
1Y
2.9%